• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

综述岩藻黄质对非酒精性脂肪性肝病的影响。

A Review of the Effects of Fucoxanthin on NAFLD.

机构信息

Department of Biochemistry, Faculty of Medicine, Universiti Kebangsaan Malaysia, Bandar Tun Razak, Cheras, Kuala Lumpur 56000, Malaysia.

Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Bandar Tun Razak, Cheras, Kuala Lumpur 56000, Malaysia.

出版信息

Nutrients. 2023 Apr 19;15(8):1954. doi: 10.3390/nu15081954.

DOI:10.3390/nu15081954
PMID:37111187
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10146066/
Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease. Fucoxanthin, a red-orange marine carotenoid, is found in natural marine seaweeds with high antioxidant activity and several other remarkable biological features. The aim of this review is to gather evidence of the positive benefits of fucoxanthin on NAFLD. Fucoxanthin provides an extensive list of physiological and biological properties, such as hepatoprotective, anti-obesity, anti-tumor, and anti-diabetes properties, in addition to antioxidant and anti-inflammatory properties. This review focuses on published research on the preventative effects of fucoxanthin on NAFLD from the perspective of human clinical trials, animal experiments , and cell investigations. Using a variety of experimental designs, including treatment dosage, experiment model, and experimental periods, the positive effects of fucoxanthin were demonstrated. Fucoxanthin's biological activities were outlined, with an emphasis on its therapeutic efficacy in NAFLD. Fucoxanthin showed beneficial effects in modulating lipid metabolism, lipogenesis, fatty acid oxidation, adipogenesis, and oxidative stress on NAFLD. A deeper comprehension of NAFLD pathogenesis is essential for the development of novel and effective therapeutic strategies.

摘要

非酒精性脂肪性肝病(NAFLD)是最常见的慢性肝病。岩藻黄质是一种红橙色的海洋类胡萝卜素,存在于具有高抗氧化活性和其他几种显著生物学特性的天然海洋海藻中。本综述的目的是收集岩藻黄质对 NAFLD 的有益影响的证据。岩藻黄质具有广泛的生理和生物学特性,如肝保护、抗肥胖、抗肿瘤和抗糖尿病特性,以及抗氧化和抗炎特性。本综述重点关注从人体临床试验、动物实验和细胞研究的角度发表的关于岩藻黄质预防 NAFLD 的研究。使用多种实验设计,包括治疗剂量、实验模型和实验周期,证明了岩藻黄质的积极作用。概述了岩藻黄质的生物学活性,重点介绍了其在 NAFLD 中的治疗功效。岩藻黄质在调节 NAFLD 中的脂质代谢、脂肪生成、脂肪酸氧化、脂肪生成和氧化应激方面显示出有益的效果。深入了解 NAFLD 的发病机制对于开发新的有效治疗策略至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1427/10146066/23f6efd949f3/nutrients-15-01954-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1427/10146066/23f6efd949f3/nutrients-15-01954-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1427/10146066/23f6efd949f3/nutrients-15-01954-g001.jpg

相似文献

1
A Review of the Effects of Fucoxanthin on NAFLD.综述岩藻黄质对非酒精性脂肪性肝病的影响。
Nutrients. 2023 Apr 19;15(8):1954. doi: 10.3390/nu15081954.
2
Fucoxanthin Attenuates Free Fatty Acid-Induced Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism/Oxidative Stress/Inflammation via the AMPK/Nrf2/TLR4 Signaling Pathway.岩藻黄质通过调节 AMPK/Nrf2/TLR4 信号通路来减轻游离脂肪酸诱导的非酒精性脂肪性肝病中的脂质代谢/氧化应激/炎症。
Mar Drugs. 2022 Mar 25;20(4):225. doi: 10.3390/md20040225.
3
The Role of Fucoxanthin in Non-Alcoholic Fatty Liver Disease.姜黄素在非酒精性脂肪性肝病中的作用。
Int J Mol Sci. 2023 May 3;24(9):8203. doi: 10.3390/ijms24098203.
4
Anti-obesity activity of the marine carotenoid fucoxanthin.海洋类胡萝卜素岩藻黄质的抗肥胖活性。
Mar Drugs. 2015 Apr 13;13(4):2196-214. doi: 10.3390/md13042196.
5
Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, Angiogenesis Inhibition, and Autophagy Modulation.岩藻黄质通过细胞周期阻滞、细胞凋亡诱导、血管生成抑制和自噬调节发挥抗癌作用。
Int J Mol Sci. 2022 Dec 17;23(24):16091. doi: 10.3390/ijms232416091.
6
Antioxidant dietary approach in treatment of fatty liver: New insights and updates.抗氧化饮食法治疗脂肪肝:新见解与新进展。
World J Gastroenterol. 2017 Jun 21;23(23):4146-4157. doi: 10.3748/wjg.v23.i23.4146.
7
Health benefits of fucoxanthin in the prevention of chronic diseases.褐藻黄素在预防慢性病方面的健康益处。
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Nov;1865(11):158618. doi: 10.1016/j.bbalip.2020.158618. Epub 2020 Jan 10.
8
Molecular Mechanisms of Fucoxanthin in Alleviating Lipid Deposition in Metabolic Associated Fatty Liver Disease.褐藻黄素缓解代谢相关性脂肪性肝病脂沉积的分子机制。
J Agric Food Chem. 2024 May 8;72(18):10391-10405. doi: 10.1021/acs.jafc.4c00590. Epub 2024 Apr 26.
9
Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.岩藻黄质可抑制饮食诱导的非酒精性脂肪性肝炎模型小鼠的肝氧化应激、炎症和纤维化。
Biochem Biophys Res Commun. 2020 Jul 23;528(2):305-310. doi: 10.1016/j.bbrc.2020.05.050. Epub 2020 May 29.
10
Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: metabolism and bioactivities relevant to human health.褐藻和硅藻中存在的海洋类胡萝卜素——岩藻黄质:与人类健康相关的代谢和生物活性。
Mar Drugs. 2011;9(10):1806-1828. doi: 10.3390/md9101806. Epub 2011 Oct 10.

引用本文的文献

1
Self-Reported Weight Gain After the Age of 20 and Risk of Steatotic Liver Disease.20岁后自我报告的体重增加与脂肪性肝病风险
Nutrients. 2025 Aug 6;17(15):2566. doi: 10.3390/nu17152566.
2
Exploring the effect and mechanism of fucoidan on liver cancer depending on network pharmacology and experimental verification.基于网络药理学和实验验证探索岩藻依聚糖对肝癌的作用及机制。
Front Chem. 2025 Jul 16;13:1638785. doi: 10.3389/fchem.2025.1638785. eCollection 2025.
3
Effectiveness of Resmetirom in Reducing Cholesterol Levels in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.

本文引用的文献

1
Nonalcoholic fatty liver disease and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.非酒精性脂肪性肝病与肥胖症:肥胖医学协会(OMA)2022年临床实践声明(CPS)
Obes Pillars. 2022 Jul 8;3:100027. doi: 10.1016/j.obpill.2022.100027. eCollection 2022 Sep.
2
The Effects of Probiotics on Small Intestinal Microbiota Composition, Inflammatory Cytokines and Intestinal Permeability in Patients with Non-Alcoholic Fatty Liver Disease.益生菌对非酒精性脂肪性肝病患者小肠微生物群组成、炎性细胞因子及肠道通透性的影响
Biomedicines. 2023 Feb 20;11(2):640. doi: 10.3390/biomedicines11020640.
3
Resmetirom降低非酒精性脂肪性肝炎患者胆固醇水平的有效性:一项系统评价和荟萃分析。
Cureus. 2024 Oct 4;16(10):e70859. doi: 10.7759/cureus.70859. eCollection 2024 Oct.
4
17β-Estradiol protects female rats from bilateral oophorectomy-induced nonalcoholic fatty liver disease induced by improving linoleic acid metabolism alteration and gut microbiota disturbance.17β-雌二醇通过改善亚油酸代谢改变和肠道微生物群紊乱,保护雌性大鼠免受双侧卵巢切除诱导的非酒精性脂肪性肝病。
Heliyon. 2024 Apr 2;10(7):e29013. doi: 10.1016/j.heliyon.2024.e29013. eCollection 2024 Apr 15.
5
Improving Determination of Pigment Contents in Microalgae Suspension with Absorption Spectroscopy: Light Scattering Effect and Bouguer-Lambert-Beer Law.提高吸收光谱法测定微藻悬浮液中色素含量的精度:光散射效应和布格-朗伯-比尔定律。
Mar Drugs. 2023 Nov 29;21(12):619. doi: 10.3390/md21120619.
Association Between Hypertension and New-Onset Non-Alcoholic Fatty Liver Disease in Chinese Non-Obese People: A Longitudinal Cohort Study.
中国非肥胖人群中高血压与新发非酒精性脂肪性肝病的关联:一项纵向队列研究
Diabetes Metab Syndr Obes. 2023 Feb 8;16:345-363. doi: 10.2147/DMSO.S396011. eCollection 2023.
4
Fatty liver index has potential as a predictor of hypertension in the Japanese general population.在日本普通人群中,脂肪肝指数有作为高血压预测指标的潜力。
Hypertens Res. 2023 Apr;46(4):896-897. doi: 10.1038/s41440-023-01209-x. Epub 2023 Feb 7.
5
Genetic Polymorphisms and Diversity in Nonalcoholic Fatty Liver Disease (NAFLD): A Mini Review.非酒精性脂肪性肝病(NAFLD)中的基因多态性与多样性:一篇综述短文
Biomedicines. 2022 Dec 30;11(1):106. doi: 10.3390/biomedicines11010106.
6
Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment.瘦/非肥胖和肥胖个体中的非酒精性脂肪性肝病:关于患病率、发病机制、临床结局及治疗的综合综述
J Clin Transl Hepatol. 2023 Apr 28;11(2):502-515. doi: 10.14218/JCTH.2022.00204. Epub 2022 Dec 23.
7
Nonalcoholic fatty liver disease and insulin resistance in children.儿童非酒精性脂肪性肝病与胰岛素抵抗
Clin Exp Pediatr. 2023 Dec;66(12):512-519. doi: 10.3345/cep.2022.01312. Epub 2023 Jan 9.
8
Long-chain saturated fatty acids and its interaction with insulin resistance and the risk of nonalcoholic fatty liver disease in type 2 diabetes in Chinese.长链饱和脂肪酸及其与胰岛素抵抗及中国人 2 型糖尿病非酒精性脂肪肝发病风险的交互作用。
Front Endocrinol (Lausanne). 2022 Dec 7;13:1051807. doi: 10.3389/fendo.2022.1051807. eCollection 2022.
9
Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment.非酒精性脂肪性肝病(NAFLD)发病机制及天然产物的防治。
Int J Mol Sci. 2022 Dec 7;23(24):15489. doi: 10.3390/ijms232415489.
10
Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology.1 型糖尿病中非酒精性脂肪性肝病:患病率和病理生理学。
Front Endocrinol (Lausanne). 2022 Dec 1;13:1031633. doi: 10.3389/fendo.2022.1031633. eCollection 2022.